Consensus $143.81M. The company said, "The company is increasing full year revenue guidance for fiscal 2023 from $140 to $145 million to $145 and $150 million… Based on the company’s performance during the first six months, we anticipate that fiscal 2023 will be another strong year for Avid. The company’s strategic transformation is well underway, and we look forward to achieving the milestones that will position us for consistent growth in the future."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CDMO:
- Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent Developments
- Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022
- Avid Bioservices Appoints Oksana Lukash as Vice President, People
- Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference
